TOTAL VOLUME:
$134.2b
24H VOL:
$126,324,530
24H TRANSACTIONS:
2,388,728,490
OPEN INTEREST:
$1,434,646,834
406,019
Markets across
30,401
events
MATCHED EVENTS:
2,689
PLATFORM COVERAGE:
5
Polymarket:
39%
VS.
Kalshi:
61%
Closed: Aug 5, 8:48 AM EST
Polymarket
This market will resolve to "Yes" if Eli Lilly's Mounjaro total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
This market will resolve to "Yes" if Eli Lilly's Mounjaro total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Key signals include preliminary sales data leaks, management commentary during investor calls, changes in demand forecasts, and any regulatory updates affecting Mounjaro’s availability. Additionally, broader market trends, such as investor sentiment toward biotech stocks or macroeconomic factors impacting pharmaceutical spending, could shift this market. As Aug 5, 2026 approaches, any official guidance or early data releases will likely cause notable price swings.